What is the core difference between retatrutide and Zepbound?
Both compounds come from Eli Lilly and both are once-weekly injectable incretin-based metabolic agents, but they differ on two fundamental axes: how many receptors they hit, and whether you can actually be prescribed them today. Zepbound is the brand name for tirzepatide used in obesity — a dual agonist that activates the GIP and GLP-1 receptors. Retatrutide is a triple agonist that adds a third target, the glucagon receptor, on top of those same two.
That extra glucagon arm is the headline mechanistic difference. Glucagon-receptor activity is associated with increased energy expenditure and the mobilization of liver fat, which is the rationale researchers cite for why retatrutide produced unusually large effects in early trials. It is also why retatrutide is being studied not just in obesity but specifically in metabolic dysfunction-associated steatotic liver disease (MASLD). A dual GIP/GLP-1 agonist like tirzepatide does not directly engage that pathway.
The difference that matters most today, though, is regulatory rather than mechanistic. Zepbound is FDA-approved for chronic weight management — a medicine a clinician can prescribe through a regulated supply chain. Retatrutide is investigational and not FDA-approved for any use; the only lawful way to receive it is enrollment in a clinical trial. Everything that follows should be read against that asymmetry.
Which produced more weight loss in clinical trials?
The two compounds have never been compared head-to-head, so any comparison reads across separate trials rather than a direct contest. In retatrutide's Phase 2 obesity trial (Jastreboff 2023, NEJM), the 12 mg dose produced a mean weight reduction of roughly 24.2% at 48 weeks — among the largest figures reported for any pharmacological agent in obesity research to date. Zepbound's pivotal SURMOUNT-1 trial (Jastreboff 2022, NEJM) produced roughly 20.9% at the 15 mg dose over 72 weeks, alongside a mean waist-circumference reduction of about 19.9 cm.
Reading those two numbers as a ranking is methodologically unsound. The trials used different durations (48 vs 72 weeks), different dose-titration schedules, and different patient populations, and the retatrutide figure comes from a smaller, earlier-phase study. A strong Phase 2 result in a narrower population does not automatically predict Phase 3 performance in the broader, more heterogeneous populations where efficacy figures frequently regress toward the mean.
The honest summary is that both drugs move the average patient deep into clinically meaningful weight loss, and retatrutide's early mean is numerically higher — but one figure is a confirmed, approved-label result and the other is an investigational signal still awaiting Phase 3 confirmation. Those are different grades of evidence, not interchangeable data points.
How do the "responder" rates compare?
Average weight loss hides how many people actually clear meaningful thresholds, so both trials reported the share of participants reaching ≥5%, ≥10%, ≥15%, and ≥20% body-weight reductions — the "responder ladder." In SURMOUNT-1, at the 15 mg Zepbound dose over 72 weeks, 91% of participants lost at least 5% of their body weight, 83.5% lost at least 10%, 70.6% lost at least 15%, and 56.7% lost at least 20%.
In the retatrutide Phase 2 trial, at the 12 mg dose over 48 weeks, every participant on the highest dose lost at least 5%, 93% lost at least 10%, and 83% lost at least 15%, with roughly two-thirds reaching 20% or more. The top of retatrutide's ladder sits a step higher than Zepbound's, particularly at the ≥15% and ≥20% rungs.
As with the headline means, these ladders come from two different trials with different lengths and populations and were never measured against each other, so they describe each drug individually rather than naming a winner. The consistent signal across both is that a large majority of patients clear the clinically meaningful thresholds — and that retatrutide's early figures look at least as strong as the approved benchmark, pending Phase 3.
Does retatrutide really reduce liver fat?
One of retatrutide's most distinctive results sits in the liver, and it has no direct equivalent on the Zepbound label. A dedicated Phase 2a substudy in people with obesity and MASLD (Sanyal 2024, Nature Medicine) used MRI to measure liver fat and found that, after 24 weeks, retatrutide reduced relative liver-fat content by about 81% at the 8 mg dose and about 82% at 12 mg, versus essentially no change on placebo.
More striking still, the majority of participants on the higher doses reached normal liver fat — a "resolution" of steatosis — by week 24, which no one on placebo achieved. This is the clearest illustration of why the third, glucagon-receptor arm matters: glucagon signaling drives hepatic fat mobilization in a way a dual GIP/GLP-1 agonist does not directly target. It is the result driving much of the scientific interest in the molecule.
Two cautions belong here. First, this is Phase 2 data in fewer than 100 people, not a confirmatory trial. Second, MASLD is not an approved indication for retatrutide — or, separately, for Zepbound — so this is a mechanistic and research distinction, not a prescribing one. It explains why retatrutide is interesting; it does not make it available.
Beyond weight: what else is each drug approved or studied for?
This is where the two diverge most clearly in real-world terms. In December 2024 the FDA expanded Zepbound's label to include moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity — making tirzepatide the first drug approved for that specific combination. For a searcher whose weight sits alongside sleep apnea, that is a concrete, approved indication a clinician can act on today, not a future possibility.
Retatrutide has no approved indication at all, but its investigational program is unusually broad. The Phase 3 TRIUMPH program (Giblin 2026) spans four large registrational trials enrolling more than 5,800 participants across distinct populations: obesity or overweight without type 2 diabetes, obesity with type 2 diabetes, severe obesity with established cardiovascular disease, and obesity with knee osteoarthritis. Alongside that sits the MASLD liver-fat work described above.
So the "beyond weight" contrast is asymmetric in kind. Zepbound's extra reach is an approved second indication you can use now (OSA); retatrutide's is a wide research agenda that may eventually translate into approvals across several conditions, but currently translates into none. Breadth of ambition is not the same as breadth of availability.
How are retatrutide and Zepbound dosed, and can you get them?
Both are once-weekly subcutaneous injections, but only one has an approved schedule. Zepbound starts at 2.5 mg once weekly for four weeks — an introductory dose meant to limit nausea rather than to drive weight loss — then steps up to 5 mg, and can be increased in 2.5 mg increments no sooner than every four weeks. The approved maintenance doses are 5, 10, or 15 mg once weekly, and the maximum is 15 mg weekly. A clinician can follow that titration today.
Retatrutide has no approved dose because it is investigational. Its Phase 2 obesity trial tested once-weekly doses of 1, 4, 8, and 12 mg, with the higher arms reached through gradual escalation; investigators found that starting at 2 mg helped mitigate the early gastrointestinal effects — the same titrate-slowly principle that governs approved incretin drugs. Every retatrutide dose figure comes from a research protocol, not a label.
On availability the gap is absolute. Zepbound is dispensed by prescription through licensed pharmacies, though prior-authorization requirements vary by insurer and supply has fluctuated since launch. Retatrutide can be obtained lawfully only by enrolling in a clinical trial; material sold online as "research" retatrutide is explicitly labeled not for human use, is unregulated for identity, purity, or sterility, and sits entirely outside the approved supply chain.
How do the side effects compare?
The side-effect profiles look broadly similar because both drugs activate the GIP and GLP-1 receptors. The dominant adverse events in each are gastrointestinal — nausea, diarrhea, vomiting, and constipation — and in both they are dose-dependent and tend to ease as the body adapts to gradual dose escalation. In SURMOUNT-1, most participants who discontinued tirzepatide did so because of GI events; retatrutide's Phase 2 data showed a similar pattern.
There are two distinctions worth flagging. Retatrutide's Phase 2 data additionally noted dose-dependent increases in heart rate and some transient skin-sensitivity reports. Zepbound, for its part, carries a Boxed Warning about thyroid C-cell tumors observed in rodent studies (the clinical relevance in humans is unknown) and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
The largest safety difference, however, is not a specific side effect but the depth of the evidence behind each profile. Zepbound has completed Phase 3 and accumulated post-market data; retatrutide's long-term safety database is materially thinner because no Phase 3 trial has yet reported. That asymmetry in how much is known is itself a meaningful difference, and it favors the approved drug.
What is the TRIUMPH program, and what happens next for retatrutide?
Retatrutide's path to a possible approval runs through TRIUMPH, Eli Lilly's Phase 3 program of four large registrational trials enrolling more than 5,800 participants in total (Giblin 2026). The four trials target distinct populations: obesity or overweight without type 2 diabetes, obesity with type 2 diabetes, severe obesity with established cardiovascular disease, and obesity with knee osteoarthritis.
That breadth matters because Phase 3 trials test efficacy and safety in larger, more representative populations than Phase 2 — and weight-loss figures often moderate as populations widen. Until these trials report and a regulator reviews them, every retatrutide result, including the striking Phase 2 weight-loss and liver-fat numbers, remains investigational, with no announced approval date.
Zepbound, by contrast, has already crossed this finish line: tirzepatide earned obesity approval in November 2023 and added the OSA indication in December 2024. That is the central asymmetry of this comparison — one drug is approved and accumulating real-world data, while the other is still running the trials that will decide whether its early promise holds.
Which one should you consider?
For anyone making a decision today, the comparison is lopsided in one specific sense: Zepbound is an option you can actually be prescribed, with an approved obesity label (and a sleep-apnea indication), a regulated supply chain, and accumulating post-market safety data. Retatrutide is not — it cannot be obtained outside a clinical trial, and material sold online as "research" retatrutide sits entirely outside that safety framework.
If the question is "what could I use, with my clinician, now," Zepbound is the answer with evidence and an approval behind it. If the question is "what does the science suggest is coming," retatrutide's Phase 2 weight-loss and liver-fat numbers are genuinely notable — but "promising in Phase 2" and "proven and approved" are very different standards, and the gap between them is exactly what the TRIUMPH program exists to test.
Either way, this decision belongs with a licensed clinician who can weigh your history, comorbidities such as sleep apnea, goals, and risk factors — including the Boxed Warning and contraindications that apply to Zepbound. Nothing here is medical advice or an endorsement of any specific drug.
Tracking either compound on PeptidePanel
Whether a clinician prescribes Zepbound, another GLP-1-class medication, or a compound within a clinical trial, the monitoring work is the same: logging doses on schedule, tracking the biomarkers that reflect metabolic progress and safety (weight trend, HbA1c, liver enzymes, lipid panel, fasting glucose), and catching side effects early enough to adjust. PeptidePanel is the neutral tracking layer for that work — it records the protocol your clinician defines, charts your bloodwork against reference ranges, and keeps your dosing log organized.
PeptidePanel does not source, supply, sell, or prescribe any compound. It is a monitoring tool for the protocol a qualified prescriber has put you on.